Advertisement

Search Results

Advertisement



Your search for all items matches 24070 pages

Showing 1 - 50


sarcoma

Complexity of Designing Clinical Trials for Sarcoma: Shifting Focus to Constellation of Subtypes

Sarcoma has bedeviled researchers for many years because of its heterogeneity. Sarcoma encompasses more than 100 different subtypes, which makes it difficult to design studies to identify effective therapies. As researchers dig deeper into the constellation of subtypes of sarcoma, some therapies...

colorectal cancer

Statins Reduced Risk of Colorectal Cancer in Meta-analysis

A systemic meta-analysis has shown that statin users had a significantly reduced risk of colorectal cancer. The study included patients with and without inflammatory bowel disease, which is associated with an increased risk of this type of cancer. The largest chemopreventive effect was observed in...

prostate cancer
genomics/genetics

Study Shows Regional Variation in Genomic Testing for Men With Prostate Cancer

A study published by Michael S. Leapman, MD, and colleagues in JAMA Oncology found substantial regional variation in the use of genomic testing for prostate cancer, raising questions about access and other factors that might promote rapid adoption of new cancer technologies. “Little was known...

lung cancer
genomics/genetics

Native American Ancestry May Impact Somatic Alterations Among Latin American Patients With Lung Cancer

A research brief by Carrot-Zhang et al published in Cancer Discovery investigating inherited lung cancer risk—especially in nonsmokers—in Latin America has found that independent of smoking status, variation in EGFR and KRAS mutation frequency in Latin American patients with lung cancer was...

prostate cancer

Association of Fall and Fracture Risk With Androgen Receptor Inhibitor Therapy for Prostate Cancer

In a systematic review and meta-analysis reported in JAMA Network Open, Myint et al found that androgen receptor inhibitor therapy for prostate cancer was associated with an increased risk of both falls and fractures. Study Details The meta-analysis included 11 randomized trials reported through...

issues in oncology
covid-19
hematologic malignancies
immunotherapy

Study Explores Duration of Shedding of Viable SARS-CoV-2 in Patients With Cancer After Immunosuppressive Therapy

In a single-institution study reported in a letter to the editor in The New England Journal of Medicine, Aydillo et al found that SARS-CoV-2 RNA could be detected in patients with COVID-19 receiving immunosuppressive treatment for cancer for as long as 78 days after the onset of virus symptoms. The ...

lymphoma
leukemia
hepatobiliary cancer
symptom management
lung cancer
immunotherapy

FDA Pipeline: Agents in DLBCL, SCLC, AML, and More

Recently, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions for agents to treat diffuse large B-cell lymphoma (DLBCL), small cell lung cancer (SCLC), acute myeloid leukemia (AML), biliary tract cancer, and graft-vs-host disease. Priority Review for Loncastuximab Tesirine...

gynecologic cancers
immunotherapy

ESMO Asia 2020: Subgroup Analysis of Japanese Patients With Ovarian Cancer Treated With Maintenance Olaparib/Bevacizumab

Findings from a subgroup analysis of the phase III PAOLA-1/ENGOT-ov25 study presented by Fujiwara et al at the ESMO Asia Virtual Congress 2020 showed that the addition of olaparib to bevacizumab maintenance following standard platinum-based therapy plus bevacizumab provided a progression-free...

issues in oncology
survivorship

Social Needs May Be Linked to Low Health-Related Quality of Life Among Black Cancer Survivors

Social needs—such as food and economic insecurity, poor housing and neighborhood conditions, and lack of access to transportation—were common in a group of Black cancer survivors in Detroit. These factors were associated with lower health-related quality of life, according to findings published by...

solid tumors

Definitive SBRT and Outcomes in Adult Patients With Extracranial Oligometastasis

In a retrospective case series reported in JAMA Network Open, Poon et al found that definitive stereotactic body radiotherapy (SBRT) was associated with good long-term overall survival and delayed widespread disease progression—but “modest” progression-free survival—in adults with extracranial...

breast cancer
palliative care

End-of-Life Care Among Commercially Insured Women Younger Than 65 With Metastatic Breast Cancer

In a study reported in JCO Oncology Practice, Ferrario et al found a sizable increase in end-of-life intensive care unit (ICU) admissions and a small but significant increase in emergency department visits over time among commercially insured women younger than age 65 with metastatic breast cancer...

Expert Point of View: Brooks D. Cash, MD

Brooks D. Cash, MD, Chief of Gastroenterology, Hepatology & Nutrition at McGovern Medical School at UTHealth in Houston, moderated the plenary session during the virtual edition of the American College of Gastroenterology 2020 Annual Scientific Meeting, where the data were presented. He...

sarcoma

Preoperative Radiotherapy Dose Reduction in Patients With Myxoid Liposarcoma

In the phase II DOREMY trial reported in JAMA Oncology, Lansu et al found that a reduction in preoperative radiotherapy dose was effective and associated with reduced morbidity in patients with myxoid liposarcoma. A stated by the investigators, “Currently, preoperative radiotherapy for all...

immunotherapy

Managing Checkpoint Inhibitor–Mediated Colitis: Vedolizumab vs Infliximab

For patients who develop severe diarrhea or colitis while receiving checkpoint inhibitors, the immunosuppressive agent vedolizumab is preferred over infliximab, according to an expert on the topic from The University of Texas MD Anderson Cancer Center. A retrospective comparison of outcomes with...

thyroid cancer

FDA Approves Pralsetinib for RET-Altered Thyroid Cancers

On December 1, the U.S. Food and Drug Administration (FDA) approved pralsetinib (Gavreto) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy, or for patients with RET fusion–positive thyroid cancer...

prostate cancer

FDA Approves Gallium-68 PSMA-11 for PSMA-Targeted PET Imaging in Prostate Cancer

On December 1, the U.S. Food and Drug Administration (FDA) approved gallium-68 PSMA-11—the first drug for positron-emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Gallium-68 PSMA-11 is indicated for patients with suspected ...

head and neck cancer
immunotherapy

ESMO Asia 2020: Phase II Study of Combination Immunotherapy for Advanced Nasopharyngeal Cancer

Dual CTLA-4/PD-1 blockade with ipilimumab plus nivolumab provided durable responses in patients with recurrent or metastatic nasopharyngeal carcinoma, according to updated efficacy and safety findings from a phase II study presented by Kao et al at ESMO Asia Virtual Congress 2020 (Abstract 266O)....

cns cancers
immunotherapy

Does Concurrent Treatment With Dexamethasone Diminish the Efficacy of Immune Checkpoint Inhibitors in Patients With Glioblastoma?

Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival, according to results of a study published by Iorgulescu et al in Clinical Cancer Research....

covid-19

FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

The U.S. Food and Drug Administration (FDA) has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) for December 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna Inc. “In keeping with the FDA’s commitment ...

gastroesophageal cancer
gastrointestinal cancer
immunotherapy

Avelumab Maintenance vs Continued Chemotherapy After First-Line Induction for Advanced Gastric Cancer

As reported in the Journal of Clinical Oncology by Markus Moehler, MD, and colleagues, the phase III JAVELIN Gastric 100 trial showed no improvement in overall survival with avelumab maintenance vs continued chemotherapy after first-line induction in HER2-negative, unresectable, locally advanced or ...

multiple myeloma

Discordance Among Risk Models for Smoldering Multiple Myeloma

In a study reported as a research letter in JAMA Oncology, Hill et al found a low degree of concordance in risk categorization among commonly used smoldering multiple myeloma risk models. Study Details The study involved application of the Mayo Clinic Risk Stratification Model 2008, the Programa...

breast cancer
gynecologic cancers
genomics/genetics

Trends in Positive BRCA Test Results Among Women Aged 65 and Older in the United States

In a study reported in JAMA Network Open, Guo et al found that the proportion of positive BRCA genetic test results markedly declined between 2008 and 2018 among women aged ≥ 65 years in the United States, with the trend likely reflecting what the investigators call a loosening of testing criteria...

colorectal cancer

ESMO Asia 2020: Performance of Immunoscore in Asian Patients With Early-Stage Colon Cancer

The Immunoscore assay can assess the risk of disease recurrence in Asian patients with early-stage colon cancer and may be used together with TNM classification to guide clinical decision-making, according to findings presented at the European Society for Medical Oncology (ESMO) Asia Virtual...

breast cancer

No Reduction in Recurrence Risk With Perioperative Aromatase Inhibitor Therapy in Postmenopausal Patients With HR-Positive Breast Cancer

As reported in The Lancet Oncology by Ian E. Smith, MD, and colleagues, the phase III POETIC trial found that perioperative aromatase inhibitor therapy did not reduce the risk of disease recurrence in postmenopausal women with hormone receptor (HR)-positive early breast cancer vs no perioperative...

breast cancer
survivorship
issues in oncology

Effect of Fertility Preservation on Reproductive Outcomes in Patients After Breast Cancer

In a Swedish nationwide cohort study reported in JAMA Oncology, Marklund et al found that women who had undergone fertility preservation had a higher live birth rate, were more likely to use assisted reproductive technology, and had better overall survival after breast cancer than women who had not ...

issues in oncology

Case Series Study Explores Experiences of Transgender Patients With Cancer

In a retrospective case series reported in JAMA Oncology, Burns et al described clinical characteristics, treatment, experiences, and outcomes among transgender patients with cancer. As stated by the investigators, “Approximately 0.5% to 0.6% of the U.S. population identify as transgender, defined...

skin cancer
immunotherapy

Machine Learning Algorithms May Help Predict Response to Immunotherapy in Patients With Advanced Melanoma

A study investigating a computational method that integrates deep learning on histology specimens with clinicodemographic variables has found that the artificial intelligence may help predict response to immune checkpoint blockade among patients with advanced melanoma. This computational approach...

solid tumors
immunotherapy

FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow

On November 25, the U.S. Food and Drug Administration (FDA) granted accelerated approval to naxitamab (Danyelza) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients aged 1 year and older and adult patients with relapsed or refractory high-risk...

Conquer Cancer®

When you donate to Conquer Cancer®, the ASCO Foundation by December 31, you help patients everywhere maintain access to critical programs and research breakthroughs for all types of cancer. Give today at CONQUER.ORG.  © 2020. American Society of Clinical Oncology. All rights reserved.

ASCO’s Free App for Patients: Cancer.Net Mobile

Tell your patients about the award-winning mobile app from Cancer.Net! This intuitive, on-the-go tool helps patients and caregivers plan and manage cancer care—from diagnosis through treatment and beyond. Make sure your patients are getting the latest trusted, oncologist-approved cancer information ...

ASCO Launches Educational Series on Social Determinants of Health

As part of its ongoing commitment to addressing inequities in cancer care and research, ASCO has launched an educational series focused on the role of social determinants of health in cancer care and outcomes. The free series, which kicked off in October, will help educate oncology trainees and...

New Global Survey Finds More Education Needed to Increase Provider Geriatric Assessments for Older Adults With Cancer

Oncology providers familiar with ASCO’s guideline on older adults with cancer are two to four times more likely to conduct a geriatric assessment on patients with cancer over the age of 65, according to the first international ASCO survey aimed at determining if and how often cancer providers are...

Time Is Running Out: Prepare for 2021 E&M Changes Today

Significant changes are coming to the office and outpatient Evaluation and Management (E&M) services Current Procedural Terminology (CPT®) codes (99202-99215). Practices, physicians, and staff who have not done so already must begin preparing for these changes today to ensure a successful...

issues in oncology

Gateway for Cancer Research and Conquer Cancer Offer Grant Funding to Research Health Disparities

Gateway for Cancer Research® is investing $1.5 million to ensure that a more diverse patient population is represented in oncology research and to expand clinical trial access for patients from underserved and underrepresented communities. The second biennial Gateway Discovery Grant, administered...

Job Loss During Cancer: How to Cope and Continue Treatment

Job loss is stressful no matter the circumstances. Recently, millions of people have lost their jobs during the COVID-19 pandemic. To make matters more difficult, job loss in the United States can often mean a loss of health insurance. For people with cancer, losing a job is especially challenging...

ELNEC Project Reaches Historic Milestone in End-of-Life Care

The End-of-Life Nursing Education Consortium (ELNEC) project is ending 2020 by surpassing a goal established 20 years ago, reporting more than 1 million nurses and other professionals trained using the ELNEC curriculum. Administered through a partnership between the American Association of Colleges ...

Rogel Team at University of Michigan Receives $11.2M to Leverage the Microbiome Against Graft-vs-Host Disease

A team of researchers from the University of Michigan Rogel Cancer Center in Ann Arbor received an $11.2 million grant from the National Heart, Lung, and Blood Institute to study how to use the microbiome to limit complications of stem cell transplants for blood cancers and other diseases....

colorectal cancer

U. S. Multisociety Task Force on Colorectal Cancer Offers Management Strategies for Malignant Colorectal Polyps

Early identification and removal of cancerous colorectal polyps are critical to preventing the progression of colorectal cancer and improving survival rates. The U.S. Multisociety Task Force on Colorectal Cancer has released new guidance for endoscopists on how to assess colorectal lesions for...

Global Cancer Institute Extends Programs to Bangladesh for Underserved Patients With Cancer

Global Cancer Institute (GCI), which is focused on improving survival rates for underserved patients with cancer worldwide, recently announced it has extended its programs to Bangladesh. The extension begins with the launch of monthly tumor boards, which help physicians and oncologists in...

skin cancer

Expect Questions About Mohs Micrographic Surgery

A recent study finding similar overall survival rates for patients with melanomas of the trunk and extremities treated with Mohs micrographic surgery or wide local excision1 raises questions about why and when physicians might recommend, and patients opt for, one or the other procedure. “The most...

skin cancer

Mohs Surgery vs Wide Local Excision for Trunk and Extremity Melanomas: Comparable Overall Survival Rates

A cohort study of 188,862 cases of all-stage melanomas of the trunk and extremities found no differences in overall survival between patients treated with Mohs micrographic surgery or with wide local excision.1 “These findings add to the existing body of evidence demonstrating that wide local...

breast cancer

Yes, Men Get Breast Cancer, Too

You could call it a sixth sense, but the moment I felt a lump in my left breast I knew it was cancer, although it would take several weeks to confirm the diagnosis. When I saw my primary cancer physician and told him of my concern, he said: “Don’t worry. Men don’t get breast cancer; it’s a woman’s...

Penn Medicine Researchers Receive $5.4 Million Grant to Find Genetic Drivers of Testicular Cancer

The international hunt to find more genetic risk markers for testicular cancer is expanding. A team of researchers led by Katherine L. Nathanson, MD, Deputy Director of the Abramson Cancer Center and the Pearl Basser Professor for BRCA-Related Research in the Perelman School of Medicine at the...

SIO and ASCO Collaborate to Develop Evidence-Based Guidelines for Integrative Therapies for Oncology

The Society for Integrative Oncology (SIO) has announced its collaboration with ASCO in the development of a series of evidence-based clinical practice guidelines for integrative therapies in oncology care. The guidelines, planned for publication in 2021 and 2022, will provide clinicians and...

Mount Sinai Receives $4 Million Gift to Support Prostate Health and Urology Department

Mount Sinai has received a $4 million donation from Lizzie and Jonathan Tisch to support prostate health and the Milton and Carroll Petrie Department of Urology at Mount Sinai. The prostate program—founded by Ash Tewari, MBBS, MCh, Kyung Hyun Kim, MD Professor and Chair of Urology—will be named the ...

kidney cancer

No Benefit of Adjuvant Sorafenib in Intermediate- or High-Risk Renal Cell Carcinoma

In a phase III trial (SORCE) reported in the Journal of Clinical Oncology, Tim Eisen, FMedSci, FRCP, PhD, of Cambridge University Hospitals NHS Foundation Trust, and colleagues found no disease-free survival benefit with 3 years of sorafenib vs placebo as adjuvant therapy in patients with renal...

South Florida Cancer Experts Make the Move to Sylvester

Four experienced oncologists who have been treating patients with cancer in South Florida for many years are joining Sylvester Comprehensive Cancer Center, part of the University of Miami Health System and the region’s only cancer center to achieve a National Cancer Institute (NCI) designation....

FDA Offers Guidance to Enhance Diversity in Clinical Trials, Encourage Inclusivity in Medical Product Development

Stephen M. Hahn, MD, Commissioner at the U.S. Food and Drug Administration (FDA), recently issued a statement regarding an important step that researchers and medical product sponsors can take to make sure clinical trials for medical products are more inclusive of multiple populations. “We have...

health-care policy

Medicaid Expansion May Be Linked to Lower Mortality Rates for Three Major Types of Cancer

In states that have expanded Medicaid availability as part of the Affordable Care Act (ACA), mortality rates for three major types of cancer are significantly lower than in states that have not expanded Medicaid availability, according to a recent study by researchers at Dana-Farber Cancer...

A Daughter of Immigrants Chooses a Challenging but Rewarding Career in Surgical Oncology

Nationally recognized oncologic surgeon Sandra L. Wong, MD, MS, FASCO, FACS, was born and raised in Stockton, California, a city on the San Joaquin River, in California’s Central Valley. “My parents were both immigrants, but unlike the stereotypical picture of hard-driving immigrant parents who...

Advertisement

Advertisement



Advertisement